O
Osamu Kainuma
Researcher at Chiba University
Publications - 92
Citations - 2372
Osamu Kainuma is an academic researcher from Chiba University. The author has contributed to research in topics: Cancer & Pancreaticoduodenectomy. The author has an hindex of 20, co-authored 91 publications receiving 2051 citations. Previous affiliations of Osamu Kainuma include Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
Katsuhiko Uesaka,Narikazu Boku,Akira Fukutomi,Yukiyasu Okamura,Masaru Konishi,Ippei Matsumoto,Yuji Kaneoka,Yasuhiro Shimizu,Shoji Nakamori,Hirohiko Sakamoto,Soichiro Morinaga,Osamu Kainuma,Koji Imai,Naohiro Sata,Shoichi Hishinuma,Hitoshi Ojima,Ryuzo Yamaguchi,Satoshi Hirano,Takeshi Sudo,Yasuo Ohashi +19 more
TL;DR: This study found that adjuvant chemotherapy with S-1 can be a new standard care for resected pancreatic cancer in Japanese patients and estimated overall and relapse-free survival using the Kaplan-Meier methods and assessed non-inferiority of S-2 to gemcitabine using the Cox proportional hazard model.
Journal ArticleDOI
High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer
Hideaki Shimada,Nobuhiro Takiguchi,Osamu Kainuma,Hiroaki Soda,Atsushi Ikeda,Akihiro Cho,Akinari Miyazaki,Hisashi Gunji,Hiroshi Yamamoto,Matsuo Nagata +9 more
TL;DR: A high preoperative NLR may be a convenient biomarker to identify patients with a poor prognosis after resection for primary gastric cancer, and was an independent risk factor for reduced survival on multivariate analysis.
Journal ArticleDOI
Comparison of laparoscopy-assisted and open pylorus-preserving pancreaticoduodenectomy for periampullary disease.
Akihiro Cho,Hiroshi Yamamoto,Matsuo Nagata,Nobuhiro Takiguchi,Hideaki Shimada,Osamu Kainuma,Hiroaki Souda,Hisashi Gunji,Akinari Miyazaki,Atsushi Ikeda,Tomoko Tohma,Ikuko Matsumoto +11 more
TL;DR: Laroscopy-assisted pancreaticoduodenectomy is on the same level with conventional open surgery in terms of perioperative outcomes or treatment efficacy.
Journal ArticleDOI
Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer.
Makoto Shinoto,Makoto Shinoto,Makoto Shinoto,Shigeru Yamada,Kotaro Terashima,Shigeo Yasuda,Yoshiyuki Shioyama,Hiroshi Honda,Tadashi Kamada,Hirohiko Tsujii,Hiromitsu Saisho,Takehide Asano,Taketo Yamaguchi,Hodaka Amano,Takeshi Ishihara,Masayuki Otsuka,Masamichi Matsuda,Osamu Kainuma,Akihiro Funakoshi,Junji Furuse,Toshio Nakagori,Takuji Okusaka,Hiroshi Ishii,Tatsuya Nagakawa,Shinichiro Takahashi,Shoichi Hishinuma,Masafumi Nakamura,Hirofumi Saito,Kiyoshi Ohara,Shinichi Ohkawa,Masahiro Hiraoka +30 more
TL;DR: Carbon ion RT with concurrent full-dose gemcitabine was well tolerated and effective in patients with unresectable locally advanced pancreatic cancer.
Journal ArticleDOI
Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study).
Katsuhiko Uesaka,Akira Fukutomi,Narikazu Boku,Hideyuki Kanemoto,Masaru Konishi,Ippei Matsumoto,Yuji Kaneoka,Yasuhiro Shimizu,Shoji Nakamori,Hirohiko Sakamoto,Soichiro Morinaga,Osamu Kainuma,Koji Imai,Naohiro Sata,Shoichi Hishinuma,Takayuki Nakamura,Michio Kanai,Satoshi Hirano,Yukinobu Yoshikawa,Yasuo Ohashi +19 more
TL;DR: It is shown that S-1 is an oral fluoropyrimidine, and shown to be non-inferior to GEM on overall survival (OS) for unresectable PC, which is a standard treatment for resected pancreatic cancer.